DAX20.483 -5,7%ESt504.840 -5,4%Top 10 Crypto11,08 +0,9%Dow40.546 -4,0%Nas16.551 -6,0%Bitcoin74.279 -1,3%Euro1,1073 +0,2%Öl64,34 -7,8%Gold3.111 -0,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Tesla A1CX3T NVIDIA 918422 Rheinmetall 703000 Apple 865985 Amazon 906866 RENK RENK73 Mercedes-Benz Group (ex Daimler) 710000 Volkswagen (VW) vz. 766403 Deutsche Bank 514000 Lufthansa 823212 Nike 866993 BASF BASF11 Microsoft 870747 Infineon 623100 HENSOLDT HAG000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Zoll-Eskalation löst Crash aus: DAX bricht massiv ein -- Nikkei tiefrot -- US-Zölle: China schlägt zurück -- Aktien von Rheinmetall, RENK & HENSOLDT ins Minus gedreht -- Novo Nordisk, Apple im Fokus
Top News
China beschließt Gegenzölle von 34 Prozent auf US-Produkte China beschließt Gegenzölle von 34 Prozent auf US-Produkte
Zeitweise fast -6%: DAX-Crash - China wehrt sich gegen US-Zölle Zeitweise fast -6%: DAX-Crash - China wehrt sich gegen US-Zölle
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Von der Zockerin zur langfristigen Investorin - wie Finanzjournalistin und Moderatorin Jessica Schwarzer ihre Leidenschaft für die Börse zum Beruf machte.

Halozyme Therapeutics Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
55,74 EUR -0,64 EUR -1,14 %
FSE
60,51 USD -2,51 USD -3,98 %
vorbörslich
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.6,92 Mrd. EUR

KGV13,93Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA0DLHS

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS40637H1095

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolHALO

Halozyme Therapeutics Aktien News

DatumMeistgelesen
PR NewswireHalozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
PR NewswireHalozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types
PR NewswireHalozyme to Host Investor Business Forum and Long-Term Outlook Call
PR NewswireHalozyme to Present at Upcoming Investor Conferences
PR NewswireHalozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia Gravis
PR NewswireHALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS
PR NewswireHalozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer's Disease
PR NewswireHalozyme To Report Third Quarter 2023 Financial and Operating Results
PR NewswirePositive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Cle...
PR NewswireUpdate: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opport...
PR NewswireHalozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery
PR NewswireHalozyme to Present at Upcoming Investor Conferences
PR NewswireHalozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain
PR NewswireHALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS
PR NewswireHalozyme To Report Second Quarter 2023 Financial and Operating Results
PR NewswirePositive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
PR NewswirePositive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis
PR NewswireHalozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis
PR NewswireCanadian Investment Regulatory Organization Trading Halt - HALO
PR NewswireCanadian Investment Regulatory Organization Trading Halt - HALO
PR NewswireHalozyme to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
PR NewswireHALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING RESULTS
PR NewswireHalozyme to Present at Upcoming Investor Conferences
PR NewswireHalozyme To Report First Quarter 2023 Financial and Operating Results
PR NewswireHALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE
PR NewswireHALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS
PR NewswireHalozyme to Report Fourth Quarter and Full Year 2022 Financial and Operating Results
PR NewswireHalozyme Appoints Barbara Duncan to its Board of Directors
PR NewswireHALOZYME THERAPEUTICS, INC. ANNOUNCES REDEMPTION OF 1.25% CONVERTIBLE SENIOR NOTES DUE 2024
PR NewswireHalozyme Provides 2023 Financial Guidance and Outlook
PR NewswireHalozyme to Present at the 41st Annual J.P. Morgan Healthcare Conference
PR NewswireHalo Collective Reports Highest Selling Quarter for Budega Retail Locations and Plans to Continue Expansion
PR NewswireHalo Collective Reports Third Quarter 2022 Financial Results
PR NewswireHalo Collective Enters into Convertible Promissory Note for Aggregate Principal Amount of Up To C$5 Million
PR NewswireHalozyme to Participate in Upcoming Investor Conferences
PR NewswireHALOZYME REPORTS THIRD QUARTER 2022 FINANCIAL AND OPERATING RESULTS
PR NewswireHalozyme to Report Third Quarter 2022 Financial and Operating Results
PR NewswireHalo Announces Update to Proposed Share Consolidation
PR NewswireHalo Collective Completes Acquisition of Premium Indoor Grow and Distribution Hub in Portland, Oregon
PR NewswireHalo Collective and Alpha Blue Ocean Agree to Early Termination of Loan and Convertible Debentures Agreements
Wer­bung

Halozyme Therapeutics News

Halozyme Therapeutics News: auf dieser Seite finden Sie alle Halozyme Therapeutics News und Nachrichten zur Halozyme Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Halozyme Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Halozyme Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.